IL-23 upregulation in the mucosa of IBD patients resistant to anti-TNFα antibody and VDZ treatments [23, 24] may account for the low discontinuation rate despite high rates of prior biologic failure in patients initiating UST. This evidence concerns the gene TNF and inflammatory bowel disease.